



Sample Information

Patient Name: 潘美雪
Gender: Female
ID No.: F222954292
History No.: 15597929
Age: 64

Ordering Doctor: DOC2397H 張睿甦
Ordering REQ.: 0BYVPWE
Signing in Date: 2022/08/18

Path No.: S111-97851
MP No.: TM22009
Assay: Oncomine Tumor Mutation Load Assay
Sample Type: FFPE
Block No.: S111-10220E
Percentage of tumor cells: 30%

Reporting Doctor: DOC5466K 葉奕成 (Phone: 8#5466)

Note:

Sample Cancer Type: Colon Cancer

Table of Contents	Page
Variants (Exclude variant in Taiwan BioBank with >1% allele frequency)	2
Biomarker Descriptions	3
Relevant Therapy Summary	5
Relevant Therapy Details	7
Clinical Trials Summary	16
Alert Details	17

Report Highlights
3 Relevant Biomarkers
1 Therapies Available
3 Clinical Trials

Relevant Colon Cancer Variants

Gene	Finding
BRAF	None detected
KRAS	KRAS p.(G12V) c.35G>T
NRAS	None detected
NTRK1	None detected
NTRK3	None detected


Relevant Biomarkers

Tier	Genomic Alteration	Relevant Therapies (In this cancer type)	Relevant Therapies (In other cancer type)	Clinical Trials
IA	<i>Tumor Mutational Burden</i> 5.02 Mut/Mb measured	pembrolizumab ¹	pembrolizumab	2
IA	<i>KRAS p.(G12V) c.35G>T</i> KRAS proto-oncogene, GTPase Allele Frequency: 30.47%	None	None	1
IIC	<i>TP53 p.(R158H) c.473G>A</i> tumor protein p53 Allele Frequency: 15.83%	None	None	1

Public data sources included in relevant therapies: FDA¹, NCCN, EMA², ESMO

Tier Reference: Li et al. *Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists.* J Mol Diagn. 2017 Jan;19(1):4-23.

 Alerts informed by public data sources:  Contraindicated,  Resistance

KRAS p.(G12V) c.35G>T  cetuximab ^{1, 2}, cetuximab + chemotherapy ², panitumumab ¹, panitumumab + chemotherapy ²

Public data sources included in alerts: FDA¹, NCCN, EMA², ESMO

Prevalent cancer biomarkers without relevant evidence based on included data sources

TSC2 c.5160+1G>T

Variants (Exclude variant in Taiwan BioBank with >1% allele frequency)

DNA Sequence Variants

Gene	Amino Acid Change	Coding	Variant ID	Locus	Allele Frequency	Transcript	Variant Effect	Coverage
KRAS	p.(G12V)	c.35G>T	COSM520	chr12:25398284	30.47%	NM_033360.4	missense	1349
TSC2	p.(?)	c.5160+1G>T	.	chr16:2138141	17.65%	NM_000548.5	unknown	612
TP53	p.(R158H)	c.473G>A	COSM10690	chr17:7578457	15.83%	NM_000546.5	missense	979
ARID1A	p.(T1514=)	c.4542G>A	.	chr1:27101260	48.68%	NM_006015.6	synonymous	1857
TAL1	p.(L285=)	c.855T>C	.	chr1:47685533	3.33%	NM_003189.5	synonymous	60
FN1	p.(L1405V)	c.4213T>G	.	chr2:216256394	50.78%	NM_212482.3	missense	770
LTF	p.(R23dup)	c.68_69insAAG	.	chr3:46501284	99.85%	NM_002343.6	nonframeshift Insertion	1954
MAGI1	p.(T485=)	c.1455G>A	.	chr3:65416465	50.13%	NM_001033057.2	synonymous	1173
ATR	p.(C1923=)	c.5769C>T	.	chr3:142215332	47.75%	NM_001184.4	synonymous	1424
PDGFRA	p.(P567=)	c.1701A>G	.	chr4:55141055	99.86%	NM_006206.6	synonymous	1436
APC	p.(S1971C)	c.5912C>G	.	chr5:112177203	44.01%	NM_000038.6	missense	434
NOTCH4	p.([P271=;D272G])	c.813_815delAGAGins GGG	.	chr6:32188640	48.68%	NM_004557.4	synonymous, missense	1927
NOTCH4	p.(P271=)	c.813A>G	.	chr6:32188642	51.32%	NM_004557.4	synonymous	1927
RPS6KA2	p.(T333=)	c.999G>A	.	chr6:166873037	44.13%	NM_001006932.3	synonymous	1022

Variants (Exclude variant in Taiwan BioBank with >1% allele frequency) (continued)

DNA Sequence Variants (continued)

Gene	Amino Acid Change	Coding	Variant ID	Locus	Allele Frequency	Transcript	Variant Effect	Coverage
CSMD3	p.(L2787F)	c.8361G>T	.	chr8:113314101	11.63%	NM_198123.2	missense	800
PTPRD	p.(K1156=)	c.3468G>A	.	chr9:8471031	61.98%	NM_002839.4	synonymous	1949
TAF1L	p.(L154=)	c.462G>A	.	chr9:32635116	7.81%	NM_153809.2	synonymous	64
TAF1L	p.(D151N)	c.451G>A	.	chr9:32635127	4.17%	NM_153809.2	missense	72
BRD3	p.(S263=)	c.789G>A	.	chr9:136913502	50.54%	NM_007371.4	synonymous	1023
TCF7L2	p.(S418=)	c.1254C>T	.	chr10:114912184	44.60%	NM_001146274.2	synonymous	2000
ATM	p.(A1931=)	c.5793T>C	.	chr11:108180917	52.63%	NM_000051.3	synonymous	1997
FLI1	p.(A393T)	c.1177G>A	.	chr11:128680701	50.58%	NM_002017.5	missense	1997
ZNF384	p.(Q501Hfs*48)	c.1503delG	.	chr12:6777110	99.43%	NM_001135734.2	frameshift Deletion	525
DDIT3	p.(G58=)	c.174G>A	.	chr12:57911085	51.92%	NM_001195055.1	synonymous	547
FLT1	p.(A1024=)	c.3072A>G	.	chr13:28895702	49.24%	NM_002019.4	synonymous	1046
PML	p.(A125=)	c.375G>A	.	chr15:74290590	47.62%	NM_033238.3	synonymous	1174
IGF1R	p.(R275C)	c.823C>T	.	chr15:99434736	4.75%	NM_000875.5	missense	1999
CDH11	p.(D311G)	c.932A>G	.	chr16:65022127	48.37%	NM_001797.4	missense	215
MAF	p.(?)	c.-20CGG>G	.	chr16:79633819	66.49%	NM_005360.5	unknown	931
MAF	p.(?)	c.-23CGG>G	.	chr16:79633822	32.22%	NM_005360.5	unknown	931
RNF213	p.(S4512=)	c.13536C>T	.	chr17:78351587	5.56%	NM_001256071.3	synonymous	54
ZNF521	p.(A182=)	c.546G>A	.	chr18:22807336	47.24%	NM_015461.3	synonymous	1996
DCC	p.(R443*)	c.1327C>T	.	chr18:50683791	11.91%	NM_005215.4	nonsense	1595
AKT2	p.(A179=)	c.537C>T	.	chr19:40747881	12.33%	NM_001626.6	synonymous	73
TAF1	p.(L57=)	c.169C>T	.	chrX:70587397	43.61%	NM_004606.5	synonymous	1165
TAF1	p.(V782M)	c.2344G>A	.	chrX:70607228	5.00%	NM_004606.5	missense	60
TAF1	p.(A851V)	c.2552C>T	.	chrX:70608211	4.48%	NM_004606.5	missense	134
TAF1	p.(R1182C)	c.3544C>T	.	chrX:70617240	5.61%	NM_004606.5	missense	107
SH2D1A	p.(?)	c.-50T>C	.	chrX:123480443	40.09%	NM_002351.5	unknown	1711

Biomarker Descriptions

KRAS (KRAS proto-oncogene, GTPase)

Background: The KRAS proto-oncogene encodes a GTPase that functions in signal transduction and is a member of the RAS superfamily which also includes NRAS and HRAS. RAS proteins mediate the transmission of growth signals from the cell surface to the nucleus via the PI3K/AKT/MTOR and RAS/RAF/MEK/ERK pathways, which regulate cell division, differentiation, and survival^{1,2,3}.

Alterations and prevalence: Recurrent mutations in RAS oncogenes cause constitutive activation and are found in 20-30% of cancers. KRAS mutations are observed in up to 10-20% of uterine cancer, 30-35% of lung adenocarcinoma and colorectal cancer, and about 60%

Biomarker Descriptions (continued)

of pancreatic cancer⁴. The majority of KRAS mutations consist of point mutations occurring at G12, G13, and Q61^{4,5,6}. Mutations at A59, K117, and A146 have also been observed but are less frequent^{7,8}.

Potential relevance: The KRAS inhibitor, sotorasib⁹, is approved (2021) for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC). The FDA has granted breakthrough therapy designation (2021) to the small molecule inhibitor, adagrasib, for KRAS G12C positive in non-small cell lung cancer following prior systemic therapy¹⁰. The small molecular inhibitor, RO-5126766, was also granted breakthrough designation (2021) alone for KRAS G12V mutant non-small cell lung cancer or in combination with defactinib, for KRAS mutant endometrial carcinoma and KRAS G12V mutant non-small cell lung cancer¹¹. Additionally, onvansertib¹² was granted fast track designation (2020) for second-line treatment of patients with KRAS-mutated metastatic colorectal cancer (mCRC). The EGFR antagonists, cetuximab¹³ and panitumumab¹⁴, are contraindicated for treatment of colorectal cancer patients with KRAS mutations in exon 2 (codons 12 and 13), exon 3 (codons 59 and 61), and exon 4 (codons 117 and 146)⁸. Additionally, KRAS mutations are associated with poor prognosis in NSCLC¹⁵.

TP53 (tumor protein p53)

Background: The TP53 gene encodes the p53 tumor suppressor protein that binds to DNA and activates transcription in response to diverse cellular stresses to induce cell cycle arrest, apoptosis, or DNA repair. In unstressed cells, TP53 is kept inactive by targeted degradation via MDM2, a substrate recognition factor for ubiquitin-dependent proteolysis. Alterations in TP53 is required for oncogenesis as they result in loss of protein function and gain of transforming potential¹⁶. Germline mutations in TP53 are the underlying cause of Li-Fraumeni syndrome, a complex hereditary cancer predisposition disorder associated with early-onset cancers^{17,18}.

Alterations and prevalence: TP53 is the most frequently mutated gene in the cancer genome with approximately half of all cancers experiencing TP53 mutations. Ovarian, head and neck, esophageal, and lung squamous cancers have particularly high TP53 mutation rates (60-90%)^{4,7,19,20,21,22}. Approximately two-thirds of TP53 mutations are missense mutations and several recurrent missense mutations are common including substitutions at codons R158, R175, Y220, R248, R273, and R282^{4,7}. Invariably, recurrent missense mutations in TP53 inactivate its ability to bind DNA and activate transcription of target genes^{23,24,25,26}.

Potential relevance: The small molecule p53 reactivator, PC14586, received a fast track designation (2020) by the FDA for advanced tumors harboring a TP53 Y220C mutation²⁷. The FDA has granted fast track designation (2019) to the p53 reactivator, eprenetapopt²⁸ and breakthrough designation²⁹ (2020) in combination with azacitidine or azacitidine and venetoclax for acute myeloid leukemia patients (AML) and myelodysplastic syndrome (MDS) harboring a TP53 mutation, respectively. In addition to investigational therapies aimed at restoring wild-type TP53 activity, compounds that induce synthetic lethality are also under clinical evaluation^{30,31}. TP53 mutations confer poor prognosis in multiple blood cancers including AML, MDS, myeloproliferative neoplasms (MPN), and chronic lymphocytic leukemia (CLL)^{32,33,34,35}. In mantle cell lymphoma, TP53 mutations are associated with poor prognosis when treated with conventional therapy including hematopoietic cell transplant³⁶. Mono- and bi-allelic mutations in TP53 confer unique characteristics in MDS, with multi-hit patients also experiencing associations with complex karyotype, few co-occurring mutations, and high-risk disease presentation as well as predicted death and leukemic transformation independent of the IPSS-R staging system³⁷.

TSC2 (TSC complex subunit 2)

Background: The TSC2 gene encodes the tuberin protein. TSC2 and TSC1 (also known as hamartin) form a complex through their respective coiled-coil domains³⁸. The TSC1-TSC2 complex is a negative regulator of the mTOR signaling pathway that regulates cell growth, cell proliferation, and protein and lipid synthesis³⁹. Specifically, the TSC1-TSC2 complex acts as a GTPase activating (GAP) protein that inhibits the G-protein RHEB and keeps it in an inactivated state (RHEB-GDP). GTP bound RHEB (RHEB-GTP) is required to activate the mTOR complex 1 (mTORC1). TSC1 and TSC2 are tumor suppressor genes. Loss of function mutations in TSC1 and TSC2 lead to dysregulation of the mTOR pathway^{38,40}. Inactivating germline mutations in TSC1 and TSC2 are associated with tuberous sclerosis complex (TSC), an autosomal dominant neurocutaneous and progressive disorder that presents with multiple benign tumors in different organs³⁸.

Alterations and prevalence: Somatic mutations are observed in up to 8% of skin cutaneous melanoma, 7% of uterine corpus endometrial carcinoma, and 4% of cervical squamous cell carcinoma^{4,7}.

Potential relevance: Currently, no therapies are approved for TSC2 aberrations.

Tumor Mutational Burden

Background: Tumor mutational burden (TMB), also known as tumor mutational load (TML), is the count of somatic mutations in the DNA of cancer cells. TMB is determined by next-generation sequencing and is expressed as the number of mutations per megabase (mut/Mb) of DNA coding sequence⁴¹. Errors in DNA repair, including mutations in the POLE gene and in mismatch repair (MMR) genes, are associated with increased TMB^{42,43,44,45,46}. High TMB is associated with increased neo-antigen burden and has been linked to

Biomarker Descriptions (continued)

response to immune checkpoint inhibitors (ICIs) that target the cytotoxic T lymphocyte antigen-4 (CTLA4), programmed death protein 1 (PD1), and programmed death-ligand 1 (PD-L1) inhibitors^{47,48,49,50}.

Alterations and prevalence: In one study of over 100,000 tumor samples, the median TMB value was 3.6 mut/Mb although TMB values vary widely across cancers⁵¹. Certain childhood cancers, leukemia, glioblastoma, and neuroblastoma typically have low mutation burden and median TMB values <1 mut/Mb^{48,51}. In comparison, cancers that experience genotoxic insults including skin cancer and lung cancer have higher median TMB values of approximately 10 mut/Mb^{48,51}. For example, within non-small cell lung cancer (NSCLC), higher TMB was observed in former/current smokers (10.5 mut/Mb) relative to never smokers (0.6 mut/Mb)^{48,51,52}. There is no consensus around the definition of high and low TMB that could be applied universally to all tumor types, instead multiple sources suggest that TMB status is a cancer type specific attribute^{51,53,54}. In NSCLC, several studies have suggested establishing a threshold between low and high TMB of 10 +/- 1 mut/Mb^{55,56,57,58}.

Potential relevance: ICIs stimulate a patient's own T-cells to kill tumors and have exhibited benefits in some patients. The first ICI to be approved by the FDA was ipilimumab (2011), an anti-CTLA4 antibody indicated for the treatment of metastatic melanoma. In 2014, anti-PD-1 antibodies, nivolumab (2014) and pembrolizumab (2014), were subsequently approved for the treatment of metastatic melanoma. Pembrolizumab was also approved (2014) for advanced esophageal squamous cell carcinoma. In 2020, the indication for pembrolizumab⁵⁹ was expanded to include TMB-H (>= 10 mut/Mb) solid tumors that have progressed on prior therapy. Indications have been expanded for these ICIs to include several other cancer types including NSCLC, advanced renal cell carcinoma, classical Hodgkin lymphoma, recurrent or metastatic squamous cell carcinoma of the head and neck, urothelial carcinoma, microsatellite instability (MSI)-High or mismatch repair deficient (dMMR) colorectal cancer, and hepatocellular carcinoma. Atezolizumab (2016), avelumab (2017), and durvalumab (2017), that target programmed death-ligand 1 (PD-L1), were subsequently approved by the FDA. However, the predictive biomarkers that underlie the clinical benefits of these approved immunotherapies, including TMB, are under active investigation. Several published studies including the CheckMate 586 and CheckMate 817 clinical trials have concluded that high TMB was associated with improved response to FDA approved checkpoint inhibitors^{56,60,61}. In contrast, several promising previous trials failed to show an improvement in survival outcomes between high and low TMB including CheckMate 227 (ipilimumab + nivolumab vs. chemotherapy), CheckMate 026 (nivolumab vs. chemotherapy), KEYNOTE 189 (pembrolizumab vs. chemotherapy), KEYNOTE 021 (pembrolizumab vs. pembrolizumab + chemotherapy), and Lung-MAP (nivolumab + ipilimumab vs. nivolumab). In response, suggestions to combine TMB score with PD-L1 expression as a way to increase the predictive power for patient stratification have been reported⁶². Nivolumab alone or in combination with ipilimumab is recommended for use in NSCLC with evidence of high TMB⁶³. Pembrolizumab is indicated for use in various cancer types with evidence of metastasis including Ewing sarcoma, salivary gland neoplasms, cervical cancer, uterine sarcoma, endometrial carcinoma, thyroid cancer, ovarian cancer, esophageal cancer, esophagogastric junction cancer, breast cancer, and germ cell tumors with high TMB^{64,65,66,67,68,69,70,71,72}. TMB score estimation is affected by the utilized assays, therefore efforts are underway to develop a standardized approach for score calculation with the aim to support consistent reporting of TMB values across laboratories^{73,74,75,76}.

Relevant Therapy Summary

☒ In this cancer type
 ☐ In other cancer type
 ☒ In this cancer type and other cancer types
 ☒ No evidence

Tumor Mutational Burden

Relevant Therapy	FDA	NCCN	EMA	ESMO	Clinical Trials*
pembrolizumab	●	○	×	×	● (II)
atezolizumab	×	×	×	×	● (II)

KRAS p.(G12V) c.35G>T

Relevant Therapy	FDA	NCCN	EMA	ESMO	Clinical Trials*
IMP7068	×	×	×	×	● (I)

* Most advanced phase (IV, III, II/III, II, I/II, I) is shown and multiple clinical trials may be available.

Relevant Therapy Summary (continued)

☒ In this cancer type ☐ In other cancer type ☒ In this cancer type and other cancer types ☒ No evidence

TP53 p.(R158H) c.473G>A

Relevant Therapy	FDA	NCCN	EMA	ESMO	Clinical Trials*
IMP7068	×	×	×	×	<input checked="" type="radio"/> (I)

* Most advanced phase (IV, III, II/III, II, I/II, I) is shown and multiple clinical trials may be available.

Relevant Therapy Details

Current FDA Information

☒ In this cancer type
 ☐ In other cancer type
 ☒ In this cancer type and other cancer types

FDA information is current as of 2022-06-15. For the most up-to-date information, search www.fda.gov.

Tumor Mutational Burden

● pembrolizumab

Cancer type: Solid Tumor

Label as of: 2022-05-20

Variant class: Tumor Mutational Burden

Indications and usage:

KEYTRUDA® is a programmed death receptor-1 (PD-1)-blocking antibody indicated:

Melanoma

- for the treatment of patients with unresectable or metastatic melanoma.
- for the adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB, IIC, or III melanoma following complete resection.

Non-Small Cell Lung Cancer (NSCLC)

- in combination with pemetrexed and platinum chemotherapy, as first-line treatment of patients with metastatic nonsquamous NSCLC, with no EGFR or ALK genomic tumor aberrations.
- in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, as first-line treatment of patients with metastatic squamous NSCLC.
- as a single agent for the first-line treatment of patients with NSCLC expressing PD-L1 [Tumor Proportion Score (TPS) $\geq 1\%$] as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, and is:
 - stage III where patients are not candidates for surgical resection or definitive chemoradiation, or
 - metastatic.
- as a single agent for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS $\geq 1\%$) as determined by an FDA-approved test, with disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA®.

Head and Neck Squamous Cell Cancer (HNSCC)

- in combination with platinum and FU for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC.
- as a single agent for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥ 1] as determined by an FDA-approved test.
- as a single agent for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy.

Classical Hodgkin Lymphoma (cHL)

- for the treatment of adult patients with relapsed or refractory cHL.
- for the treatment of pediatric patients with refractory cHL, or cHL that has relapsed after 2 or more lines of therapy.

Primary Mediastinal Large B-Cell Lymphoma (PMBCL)

- for the treatment of adult and pediatric patients with refractory PMBCL, or who have relapsed after 2 or more prior lines of therapy.
- Limitations of Use: KEYTRUDA® is not recommended for treatment of patients with PMBCL who require urgent cytoreductive therapy.

Urothelial Carcinoma

Tumor Mutational Burden (continued)

- for the treatment of patients with locally advanced or metastatic urothelial carcinoma who:
 - are not eligible for any platinum-containing chemotherapy, or
 - who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy
- for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy.

Microsatellite Instability-High or Mismatch Repair Deficient Cancer

- for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options.¹
- Limitations of Use: The safety and effectiveness of KEYTRUDA® in pediatric patients with MSI-H central nervous system cancers have not been established.

Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer (CRC)

- for the treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer (CRC).

Gastric Cancer

- in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma.¹

Esophageal Cancer

- for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation either:
 - in combination with platinum- and fluoropyrimidine-based chemotherapy, or
 - as a single agent after one or more prior lines of systemic therapy for patients with tumors of squamous cell histology that express PD-L1 (CPS ≥ 10) as determined by an FDA-approved test.

Cervical Cancer

- in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS ≥ 1) as determined by an FDA-approved test.
- as a single agent for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS ≥ 1) as determined by an FDA-approved test.

Hepatocellular Carcinoma (HCC)

- for the treatment of patients with HCC who have been previously treated with sorafenib.¹

Merkel Cell Carcinoma (MCC)

- for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma.¹

Renal Cell Carcinoma (RCC)

- in combination with axitinib, for the first-line treatment of adult patients with advanced RCC.
- in combination with lenvatinib, for the first-line treatment of adult patients with advanced RCC.
- for the adjuvant treatment of patients with RCC at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.

Endometrial Carcinoma

- in combination with lenvatinib, for the treatment of patients with advanced endometrial carcinoma that is not MSI-H or dMMR, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.
- as a single agent, for the treatment of patients with advanced endometrial carcinoma that is MSI-H or dMMR, as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.

Tumor Mutational Burden-High (TMB-H) Cancer

- for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [≥ 10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options.¹

Tumor Mutational Burden (continued)

- Limitations of Use: The safety and effectiveness of KEYTRUDA® in pediatric patients with TMB-H central nervous system cancers have not been established.

Cutaneous Squamous Cell Carcinoma (cSCC)

- for the treatment of patients with recurrent or metastatic cSCC or locally advanced cSCC that is not curable by surgery or radiation.

Triple-Negative Breast Cancer (TNBC)

- for the treatment of patients with high-risk early-stage TNBC in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery.
- in combination with chemotherapy, for the treatment of patients with locally recurrent unresectable or metastatic TNBC whose tumors express PD-L1 (CPS ≥ 10) as determined by an FDA approved test.

Adult Indications: Additional Dosing Regimen of 400 mg Every 6 Weeks

- for use at an additional recommended dosage of 400 mg every 6 weeks for all approved adult indications.²

¹ This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.

² This indication is approved under accelerated approval based on pharmacokinetic data, the relationship of exposure to efficacy, and the relationship of exposure to safety. Continued approval for this dosing may be contingent upon verification and description of clinical benefit in the confirmatory trials.

Reference:

https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125514s123lbl.pdf

Current NCCN Information

- ☒ In this cancer type
 ☐ In other cancer type
 ☒ In this cancer type and other cancer types

NCCN information is current as of 2022-06-01. For the most up-to-date information, search www.nccn.org.
For NCCN International Adaptations & Translations, search www.nccn.org/global/international_adaptations.aspx.

Tumor Mutational Burden

☐ pembrolizumab

Cancer type: Chondrosarcoma, Ewing Sarcoma, Osteosarcoma **Variant class:** Tumor Mutational Burden

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Unresectable, Metastatic, Progression (Subsequent therapy); Useful in certain circumstances

Reference: NCCN Guidelines® - NCCN-Bone Cancer [Version 2.2022]

☐ pembrolizumab

Cancer type: Breast Cancer **Variant class:** Tumor Mutational Burden

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Stage IV; Invasive, Unresectable, Metastatic, Progression (Line of therapy not specified); Useful in certain circumstances

Reference: NCCN Guidelines® - NCCN-Breast Cancer [Version 3.2022]

☐ pembrolizumab

Cancer type: Cervical Small Cell Neuroendocrine Carcinoma **Variant class:** Tumor Mutational Burden

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Recurrent, Metastatic (Second-line therapy, Subsequent therapy); Useful in certain circumstances

Reference: NCCN Guidelines® - NCCN-Cervical Cancer [Version 1.2022]

☐ pembrolizumab

Cancer type: Cervical Cancer **Variant class:** Tumor Mutational Burden

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Squamous Cell, Adenocarcinoma, Adenosquamous; Recurrent, Metastatic, Progression (Second-line therapy, Subsequent therapy); Useful in certain circumstances

Reference: NCCN Guidelines® - NCCN-Cervical Cancer [Version 1.2022]

Tumor Mutational Burden (continued)

○ pembrolizumab

Cancer type: Esophageal Cancer,
Gastroesophageal Junction Adenocarcinoma

Variant class: Tumor Mutational Burden

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Adenocarcinoma, Squamous Cell; Unresectable, Locally Advanced, Recurrent, Metastatic (Second-line therapy, Subsequent therapy); Useful in certain circumstances

Reference: NCCN Guidelines® - NCCN-Esophageal and Esophagogastric Junction Cancers [Version 2.2022]

○ pembrolizumab

Cancer type: Gastric Cancer

Variant class: Tumor Mutational Burden

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Unresectable, Locally Advanced, Recurrent, Metastatic (Second-line therapy, Subsequent therapy); Useful in certain circumstances

Reference: NCCN Guidelines® - NCCN-Gastric Cancer [Version 2.2022]

○ pembrolizumab

Cancer type: Head and Neck Cancer

Variant class: Tumor Mutational Burden

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Nasopharyngeal; Recurrent, Unresectable, Metastatic (Subsequent therapy); Useful in certain circumstances
- Salivary Gland Neoplasm; Recurrent, Unresectable, Metastatic (Line of therapy not specified); Useful in certain circumstances

Reference: NCCN Guidelines® - NCCN-Head and Neck Cancers [Version 2.2022]

○ pembrolizumab

Cancer type: Extrahepatic Cholangiocarcinoma,
Gallbladder Carcinoma, Intrahepatic
Cholangiocarcinoma

Variant class: Tumor Mutational Burden

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Unresectable, Metastatic, Progression (Subsequent therapy); Useful in certain circumstances

Reference: NCCN Guidelines® - NCCN-Hepatobiliary Cancers [Version 1.2022]

Tumor Mutational Burden (continued)

○ pembrolizumab

Cancer type: Large Cell Neuroendocrine Carcinoma, Mixed Neuroendocrine Non-Neuroendocrine Neoplasm, Small Cell Neuroendocrine Carcinoma

Variant class: Tumor Mutational Burden

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Poorly Differentiated; Advanced, Progression (Line of therapy not specified); Consider

Reference: NCCN Guidelines® - NCCN-Neuroendocrine and Adrenal Tumors [Version 1.2022]

○ pembrolizumab

Cancer type: Neuroendocrine Tumor

Variant class: Tumor Mutational Burden

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Well Differentiated; G3; Locally Advanced, Metastatic, Progression, Unresectable (Line of therapy not specified)

Reference: NCCN Guidelines® - NCCN-Neuroendocrine and Adrenal Tumors [Version 1.2022]

○ pembrolizumab

Cancer type: Ovarian Cancer

Variant class: Tumor Mutational Burden

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Epithelial, Less Common Ovarian Cancers, Fallopian Tube, Primary Peritoneal; Recurrent (Recurrence therapy); Useful in certain circumstances

Reference: NCCN Guidelines® - NCCN-Ovarian Cancer [Version 1.2022]

○ pembrolizumab

Cancer type: Pancreatic Cancer

Variant class: Tumor Mutational Burden

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Adenocarcinoma; Metastatic (First-line therapy); Useful in certain circumstances
- Adenocarcinoma; Locally Advanced, Metastatic, Recurrent (Subsequent therapy); Preferred intervention

Reference: NCCN Guidelines® - NCCN-Pancreatic Adenocarcinoma [Version 1.2022]

Tumor Mutational Burden (continued)

○ pembrolizumab

Cancer type: Castration-Resistant Prostate Cancer **Variant class:** Tumor Mutational Burden

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Adenocarcinoma; Metastatic, Progression (Subsequent therapy); Useful in certain circumstances

Reference: NCCN Guidelines® - NCCN-Prostate Cancer [Version 4.2022]

○ pembrolizumab

Cancer type: Angiosarcoma

Variant class: Tumor Mutational Burden

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Advanced, Metastatic, Progression, Unresectable (Subsequent therapy); Useful in certain circumstances

Reference: NCCN Guidelines® - NCCN-Soft Tissue Sarcoma [Version 2.2022]

○ pembrolizumab

Cancer type: Myxofibrosarcoma, Undifferentiated
Pleomorphic Sarcoma, Undifferentiated Sarcoma

Variant class: Tumor Mutational Burden

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Unresectable, Advanced, Metastatic, Progression (Subsequent therapy); Useful in certain circumstances

Reference: NCCN Guidelines® - NCCN-Soft Tissue Sarcoma [Version 2.2022]

○ pembrolizumab

Cancer type: Testicular Cancer

Variant class: Tumor Mutational Burden

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Germ Cell Tumor; Metastatic, Recurrent (Third-line therapy); Useful in certain circumstances

Reference: NCCN Guidelines® - NCCN-Testicular Cancer [Version 2.2022]

Tumor Mutational Burden (continued)

○ pembrolizumab

Cancer type: Thyroid Gland Follicular Carcinoma, Thyroid Gland Hurthle Cell Carcinoma, Thyroid Gland Papillary Carcinoma

Variant class: Tumor Mutational Burden

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Locally Recurrent, Advanced, Metastatic (Line of therapy not specified); Useful in certain circumstances

Reference: NCCN Guidelines® - NCCN-Thyroid Carcinoma [Version 2.2022]

○ pembrolizumab

Cancer type: Thyroid Gland Medullary Carcinoma

Variant class: Tumor Mutational Burden

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Recurrent, Persistent, Local, Distant Metastases, Regional (Line of therapy not specified); Useful in certain circumstances

Reference: NCCN Guidelines® - NCCN-Thyroid Carcinoma [Version 2.2022]

○ pembrolizumab

Cancer type: Thyroid Gland Anaplastic Carcinoma

Variant class: Tumor Mutational Burden

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Stage IVC; Metastatic (Second-line therapy); Useful in certain circumstances, Consider

Reference: NCCN Guidelines® - NCCN-Thyroid Carcinoma [Version 2.2022]

○ pembrolizumab

Cancer type: Endometrial Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Undifferentiated and Dedifferentiated Carcinomas of the Uterine Corpus, Uterine Corpus Carcinosarcoma

Variant class: Tumor Mutational Burden

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Unresectable, Metastatic, Progression (Second-line therapy); Preferred intervention

Reference: NCCN Guidelines® - NCCN-Uterine Neoplasms [Version 1.2022]

Tumor Mutational Burden (continued)

☐ pembrolizumab

Cancer type: Uterine Sarcoma

Variant class: Tumor Mutational Burden

NCCN Recommendation category: 2A

Population segment (Line of therapy):

- Unresectable, Metastatic, Progression (Second-line therapy); Useful in certain circumstances

Reference: NCCN Guidelines® - NCCN-Uterine Neoplasms [Version 1.2022]

☐ pembrolizumab

Cancer type: Castration-Resistant Prostate Cancer

Variant class: Tumor Mutational Burden

NCCN Recommendation category: 2B

Population segment (Line of therapy):

- Adenocarcinoma; Visceral Metastases, Progression (Subsequent therapy); Useful in certain circumstances

Reference: NCCN Guidelines® - NCCN-Prostate Cancer [Version 4.2022]

Clinical Trials in Taiwan region:

Clinical Trials Summary

KRAS p.(G12V) c.35G>T + TP53 p.(R158H) c.473G>A

NCT ID	Title	Phase
NCT04768868	A Phase I, Open-Label, Multi-Center, Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of the WEE1 Inhibitor IMP7068 Monotherapy in Patients With Advanced Solid Tumors	I

Tumor Mutational Burden

NCT ID	Title	Phase
NCT04589845	Tumor-Agnostic Precision Immunooncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial	II
NCT02628067	A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158).	II

Alerts Informed By Public Data Sources

Current FDA Information

 Contraindicated
  Not recommended
  Resistance
  Breakthrough
  Fast Track

FDA information is current as of 2022-06-15. For the most up-to-date information, search www.fda.gov.

KRAS p.(G12V) c.35G>T

cetuximab

Cancer type: Colorectal Cancer

Label as of: 2021-09-24

Variant class: KRAS G12 mutation

Indications and usage:

Erbix® is an epidermal growth factor receptor (EGFR) antagonist indicated for treatment of:

Head and Neck Cancer

- Locally or regionally advanced squamous cell carcinoma of the head and neck in combination with radiation therapy.
- Recurrent locoregional disease or metastatic squamous cell carcinoma of the head and neck in combination with platinum-based therapy with fluorouracil.
- Recurrent or metastatic squamous cell carcinoma of the head and neck progressing after platinum-based therapy.

Colorectal Cancer

K-Ras wild-type, EGFR-expressing, metastatic colorectal cancer as determined by FDA-approved test

- in combination with FOLFIRI for first-line treatment,
- in combination with irinotecan in patients who are refractory to irinotecan-based chemotherapy,
- as a single agent in patients who have failed oxaliplatin- and irinotecan-based chemotherapy or who are intolerant to irinotecan.

Limitations of Use: Erbix® is not indicated for treatment of Ras-mutant colorectal cancer or when the results of the Ras mutation tests are unknown.

BRAF V600E Mutation-Positive Metastatic Colorectal Cancer (CRC)

- in combination with encorafenib, for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy.

Reference:

https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf

panitumumab

Cancer type: Colorectal Cancer

Label as of: 2021-08-25

Variant class: KRAS G12 mutation

Indications and usage:

VECTIBIX® is an epidermal growth factor receptor (EGFR) antagonist indicated for the treatment of wild-type RAS (defined as wild-type in both KRAS and NRAS as determined by an FDA-approved test for this use) metastatic colorectal cancer (mCRC):

- In combination with FOLFOX for first-line treatment.
- As monotherapy following disease progression after prior treatment with fluoropyrimidine, oxaliplatin, and irinotecan-containing chemotherapy.
- Limitation of Use:** VECTIBIX® is not indicated for the treatment of patients with RAS-mutant mCRC or for whom RAS mutation status is unknown.

Reference:

https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125147s210lbl.pdf

KRAS p.(G12V) c.35G>T (continued)

RO-5126766, defactinib + RO-5126766

Cancer type: Endometrial Carcinoma, Non-Small Cell Lung Cancer

Variant class: KRAS G12V mutation

Supporting Statement:

The FDA has granted Breakthrough Designation to the small molecule inhibitor, RO-5126766 alone for KRAS G12V mutant non-small cell lung cancer or in combination with defactinib, for KRAS mutant endometrial carcinoma and KRAS G12V mutant non-small cell lung cancer.

Reference:

<https://investor.verastem.com//news-releases/news-release-details/verastem-oncology-receives-breakthrough-therapy-designation-vs>

bevacizumab + onvansertib + FOLFIRI

Cancer type: Colorectal Cancer

Variant class: KRAS mutation


Supporting Statement:

The FDA has granted Fast Track Designation to the Polo-like Kinase 1 (PLK1) inhibitor, onvansertib, in combination with FOLFIRI and bevacizumab, for KRAS mutations in metastatic colorectal cancer in the second line.

Reference:

<https://cardiffoncology.investorroom.com/2020-05-28-Cardiff-Oncology-Announces-Fast-Track-Designation-Granted-by-the-FDA-to-Onvansertib-for-Second-Line-Treatment-of-KRAS-Mutated-Colorectal-Cancer>

Current NCCN Information

 Contraindicated

 Not recommended

 Resistance

 Breakthrough

 Fast Track

NCCN information is current as of 2022-06-01. For the most up-to-date information, search www.nccn.org. For NCCN International Adaptations & Translations, search www.nccn.org/global/international_adaptations.aspx.

Tumor Mutational Burden

pembrolizumab

Cancer type: Giant Cell Tumor of Soft Tissue

Variant class: Tumor Mutational Burden

NCCN Recommendation category: 2A

Summary:

NCCN Guidelines® include the following supporting statement(s):

- "NCCN does not recommend this systemic treatment for GCTB since it is not technically a malignant tumor."

Reference: NCCN Guidelines® - NCCN-Bone Cancer [Version 2.2022]

KRAS p.(G12V) c.35G>T**⊘ cetuximab****Cancer type:** Colon Cancer**Variant class:** KRAS exon 2 mutation**Summary:**

NCCN Guidelines® include the following supporting statement(s):

- "Patients with any known KRAS mutation (exon 2, 3, 4) or NRAS mutation (exon 2, 3, 4) should not be treated with either cetuximab or panitumumab."

Reference: NCCN Guidelines® - NCCN-Colon Cancer [Version 1.2022]**⊘ panitumumab****Cancer type:** Colon Cancer**Variant class:** KRAS exon 2 mutation**Summary:**

NCCN Guidelines® include the following supporting statement(s):

- "Patients with any known KRAS mutation (exon 2, 3, 4) or NRAS mutation (exon 2, 3, 4) should not be treated with either cetuximab or panitumumab."

Reference: NCCN Guidelines® - NCCN-Colon Cancer [Version 1.2022]**⊘ cetuximab****Cancer type:** Rectal Cancer**Variant class:** KRAS exon 2 mutation**Summary:**

NCCN Guidelines® include the following supporting statement(s):

- "Patients with any known KRAS mutation (exon 2, 3, 4) or NRAS mutation (exon 2, 3, 4) should not be treated with either cetuximab or panitumumab."

Reference: NCCN Guidelines® - NCCN-Rectal Cancer [Version 1.2022]**⊘ panitumumab****Cancer type:** Rectal Cancer**Variant class:** KRAS exon 2 mutation**Summary:**

NCCN Guidelines® include the following supporting statement(s):

- "Patients with any known KRAS mutation (exon 2, 3, 4) or NRAS mutation (exon 2, 3, 4) should not be treated with either cetuximab or panitumumab."

Reference: NCCN Guidelines® - NCCN-Rectal Cancer [Version 1.2022]

Current EMA Information

 Contraindicated
  Not recommended
  Resistance
  Breakthrough
  Fast Track

EMA information is current as of 2022-06-15. For the most up-to-date information, search www.ema.europa.eu/ema.

KRAS p.(G12V) c.35G>T

cetuximab, cetuximab + oxaliplatin

Cancer type: Colorectal Cancer

Label as of: 2022-05-25

Variant class: KRAS exon 2 mutation

Reference:

https://www.ema.europa.eu/en/documents/product-information/erbitux-epar-product-information_en.pdf

panitumumab + oxaliplatin

Cancer type: Colorectal Cancer

Label as of: 2021-12-07

Variant class: KRAS exon 2 mutation

Reference:

https://www.ema.europa.eu/en/documents/product-information/vectibix-epar-product-information_en.pdf

Current ESMO Information

 Contraindicated
  Not recommended
  Resistance
  Breakthrough
  Fast Track

ESMO information is current as of 2022-06-01. For the most up-to-date information, search www.esmo.org.

KRAS p.(G12V) c.35G>T

cetuximab

Cancer type: Colorectal Cancer

Variant class: KRAS exon 2 mutation

Summary:

ESMO Clinical Practice Guidelines include the following supporting statement:

- "It has been demonstrated that the (potential) benefit of anti-EGFR antibodies in all treatment lines and either as a single agent or in combination with any chemotherapy regimen is limited to patients in whom a RAS mutation is excluded. It was shown that the 'expanded RAS' analysis (also including the detection of mutations in exons 3 and 4 of the KRAS gene as well as mutations in the NRAS [exons 2-4] gene) is superior to the KRAS (exon 2) analysis in predicting both more efficacy in the expanded RAS wild-type (WT) patients and a potential detrimental effect in patients harbouring any RAS mutation in their tumour genome [II/A]."

Reference: ESMO Clinical Practice Guidelines - ESMO-Metastatic Colorectal Cancer [Ann Oncol (2014) 25 (suppl 3): iii1-iii9. (eUpdate: 20 September 2016; Corrigendum: 21 July 2015)]

KRAS p.(G12V) c.35G>T (continued)

⊘ cetuximab + chemotherapy

Cancer type: Colorectal Cancer

Variant class: KRAS exon 2 mutation

Summary:

ESMO Clinical Practice Guidelines include the following supporting statement:

- "It has been demonstrated that the (potential) benefit of anti-EGFR antibodies in all treatment lines and either as a single agent or in combination with any chemotherapy regimen is limited to patients in whom a RAS mutation is excluded. It was shown that the 'expanded RAS' analysis (also including the detection of mutations in exons 3 and 4 of the KRAS gene as well as mutations in the NRAS [exons 2-4] gene) is superior to the KRAS (exon 2) analysis in predicting both more efficacy in the expanded RAS wild-type (WT) patients and a potential detrimental effect in patients harbouring any RAS mutation in their tumour genome [II/A]."
- "Thus, the activity of the anti-EGFR antibodies is confined to RAS WT tumours (and not only KRAS WT tumours). This is true for the combinations of cetuximab or panitumumab alone or with irinotecan- and oxaliplatin-based regimens. Treatment with anti-EGFR antibodies may even harm patients with a RAS mutation, especially when combined with oxaliplatin [I/A]."

Reference: ESMO Clinical Practice Guidelines - ESMO-Metastatic Colorectal Cancer [Ann Oncol (2014) 25 (suppl 3): iii1-iii9. (eUpdate: 20 September 2016; Corrigendum: 21 July 2015)]

⊘ panitumumab

Cancer type: Colorectal Cancer

Variant class: KRAS exon 2 mutation

Summary:

ESMO Clinical Practice Guidelines include the following supporting statement:

- "It has been demonstrated that the (potential) benefit of anti-EGFR antibodies in all treatment lines and either as a single agent or in combination with any chemotherapy regimen is limited to patients in whom a RAS mutation is excluded. It was shown that the 'expanded RAS' analysis (also including the detection of mutations in exons 3 and 4 of the KRAS gene as well as mutations in the NRAS [exons 2-4] gene) is superior to the KRAS (exon 2) analysis in predicting both more efficacy in the expanded RAS wild-type (WT) patients and a potential detrimental effect in patients harbouring any RAS mutation in their tumour genome [II/A]."

Reference: ESMO Clinical Practice Guidelines - ESMO-Metastatic Colorectal Cancer [Ann Oncol (2014) 25 (suppl 3): iii1-iii9. (eUpdate: 20 September 2016; Corrigendum: 21 July 2015)]

⊘ panitumumab + chemotherapy

Cancer type: Colorectal Cancer

Variant class: KRAS exon 2 mutation

Summary:

ESMO Clinical Practice Guidelines include the following supporting statement:

- "It has been demonstrated that the (potential) benefit of anti-EGFR antibodies in all treatment lines and either as a single agent or in combination with any chemotherapy regimen is limited to patients in whom a RAS mutation is excluded. It was shown that the 'expanded RAS' analysis (also including the detection of mutations in exons 3 and 4 of the KRAS gene as well as mutations in the NRAS [exons 2-4] gene) is superior to the KRAS (exon 2) analysis in predicting both more efficacy in the expanded RAS wild-type (WT) patients and a potential detrimental effect in patients harbouring any RAS mutation in their tumour genome [II/A]."
- "Thus, the activity of the anti-EGFR antibodies is confined to RAS WT tumours (and not only KRAS WT tumours). This is true for the combinations of cetuximab or panitumumab alone or with irinotecan- and oxaliplatin-based regimens. Treatment with anti-EGFR antibodies may even harm patients with a RAS mutation, especially when combined with oxaliplatin [I/A]."

Reference: ESMO Clinical Practice Guidelines - ESMO-Metastatic Colorectal Cancer [Ann Oncol (2014) 25 (suppl 3): iii1-iii9. (eUpdate: 20 September 2016; Corrigendum: 21 July 2015)]

Signatures

Testing Personnel:

Laboratory Supervisor:

Pathologist:

References

1. Pylayeva-Gupta et al. RAS oncogenes: weaving a tumorigenic web. *Nat. Rev. Cancer*. 2011 Oct 13;11(11):761-74. PMID: 21993244
2. Karnoub et al. Ras oncogenes: split personalities. *Nat. Rev. Mol. Cell Biol.* 2008 Jul;9(7):517-31. PMID: 18568040
3. Scott et al. Therapeutic Approaches to RAS Mutation. *Cancer J.* 2016 May-Jun;22(3):165-74. doi: 10.1097/PPO.000000000000187. PMID: 27341593
4. Weinstein et al. The Cancer Genome Atlas Pan-Cancer analysis project. *Nat. Genet.* 2013 Oct;45(10):1113-20. PMID: 24071849
5. Román et al. KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target. *Mol Cancer*. 2018 Feb 19;17(1):33. doi: 10.1186/s12943-018-0789-x. PMID: 29455666
6. Dinu et al. Prognostic significance of KRAS gene mutations in colorectal cancer--preliminary study. *J Med Life*. 2014 Oct-Dec;7(4):581-7. PMID: 25713627
7. Cerami et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. *Cancer Discov*. 2012 May;2(5):401-4. PMID: 22588877
8. Allegra et al. Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015. *J. Clin. Oncol.* 2016 Jan 10;34(2):179-85. PMID: 26438111
9. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214665s000lbl.pdf
10. <https://ir.mirati.com/press-releases/press-release-details/2021/Mirati-Therapeutics-Adagrasib-Receives-Breakthrough-Therapy-Designation-from-U.S.-Food-and-Drug-Administration-for-Patients-with-Advanced-Non-Small-Cell-Lung-Cancer-Harboring-the-KRAS-G12C-Mutation/default.aspx>
11. <https://investor.verastem.com//news-releases/news-release-details/verastem-oncology-receives-breakthrough-therapy-designation-vs>
12. <https://cardiffoncology.investorroom.com/2020-05-28-Cardiff-Oncology-Announces-Fast-Track-Designation-Granted-by-the-FDA-to-Onvansertib-for-Second-Line-Treatment-of-KRAS-Mutated-Colorectal-Cancer>
13. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf
14. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125147s210lbl.pdf
15. Slebos et al. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. *N. Engl. J. Med.* 1990 Aug 30;323(9):561-5. PMID: 2199829
16. Muller et al. Mutant p53 in cancer: new functions and therapeutic opportunities. *Cancer Cell*. 2014 Mar 17;25(3):304-17. PMID: 24651012
17. Olivier et al. TP53 mutations in human cancers: origins, consequences, and clinical use. *Cold Spring Harb Perspect Biol.* 2010 Jan;2(1):a001008. PMID: 20182602
18. Guha et al. Inherited TP53 Mutations and the Li-Fraumeni Syndrome. *Cold Spring Harb Perspect Med.* 2017 Apr 3;7(4). PMID: 28270529
19. Peter et al. Comprehensive genomic characterization of squamous cell lung cancers. *Nature*. 2012 Sep 27;489(7417):519-25. PMID: 22960745
20. Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas. *Nature*. 2015 Jan 29;517(7536):576-82. PMID: 25631445
21. Campbell et al. Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas. *Nat. Genet.* 2016 Jun;48(6):607-16. PMID: 27158780
22. Cancer Genome Atlas Research Network. Integrated genomic characterization of oesophageal carcinoma. *Nature*. 2017 Jan 12;541(7636):169-175. doi: 10.1038/nature20805. Epub 2017 Jan 4. PMID: 28052061
23. Olivier et al. The IARC TP53 database: new online mutation analysis and recommendations to users. *Hum. Mutat.* 2002 Jun;19(6):607-14. PMID: 12007217
24. Rivlin et al. Mutations in the p53 Tumor Suppressor Gene: Important Milestones at the Various Steps of Tumorigenesis. *Genes Cancer*. 2011 Apr;2(4):466-74. PMID: 21779514
25. Petitjean et al. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. *Oncogene*. 2007 Apr 2;26(15):2157-65. PMID: 17401424
26. Soussi et al. Recommendations for analyzing and reporting TP53 gene variants in the high-throughput sequencing era. *Hum. Mutat.* 2014 Jun;35(6):766-78. PMID: 24729566
27. <https://www.globenewswire.com/news-release/2020/10/13/2107498/0/en/PMV-Pharma-Granted-FDA-Fast-Track-Designation-of-PC14586-for-the-Treatment-of-Advanced-Cancer-Patients-that-have-Tumors-with-a-p53-Y220C-Mutation.html>

References (continued)

28. <https://ir.aprea.com//news-releases/news-release-details/aprea-therapeutics-receives-fda-fast-track-designation>
29. <http://vp280.alertir.com/en/pressreleases/karolinska-development%27s-portfolio-company-aprea-therapeutics-receives-fda-breakthrough-therapy-designation-1769167>
30. Parrales et al. Targeting Oncogenic Mutant p53 for Cancer Therapy. *Front Oncol.* 2015 Dec 21;5:288. doi: 10.3389/fonc.2015.00288. eCollection 2015. PMID: 26732534
31. Zhao et al. Molecularly targeted therapies for p53-mutant cancers. *Cell. Mol. Life Sci.* 2017 Nov;74(22):4171-4187. PMID: 28643165
32. NCCN Guidelines® - NCCN-Acute Myeloid Leukemia [Version 1.2022]
33. NCCN Guidelines® - NCCN-Myelodysplastic Syndromes [Version 3.2022]
34. NCCN Guidelines® - NCCN-Myeloproliferative Neoplasms [Version 2.2022]
35. NCCN Guidelines® - NCCN-Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma [Version 2.2022]
36. NCCN Guidelines® - NCCN-B-Cell Lymphomas [Version 3.2022]
37. Bernard et al. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. *Nat. Med.* 2020 Aug 3. PMID: 32747829
38. Rosset et al. TSC1 and TSC2 gene mutations and their implications for treatment in Tuberous Sclerosis Complex: a review. *Genet Mol Biol.* 2017 Jan-Mar;40(1):69-79. PMID: 28222202
39. Henske et al. Tuberous sclerosis complex. *Nat Rev Dis Primers.* 2016 May 26;2:16035. PMID: 27226234
40. Santiago et al. Identification of regions critical for the integrity of the TSC1-TSC2-TBC1D7 complex. *PLoS ONE.* 2014;9(4):e93940. PMID: 24714658
41. Yuan et al. Novel technologies and emerging biomarkers for personalized cancer immunotherapy. 4:3. PMID: 26788324
42. Temko et al. Somatic POLE exonuclease domain mutations are early events in sporadic endometrial and colorectal carcinogenesis, determining driver mutational landscape, clonal neoantigen burden and immune response. *J. Pathol.* 2018 Jul;245(3):283-296. PMID: 29604063
43. Mehnert et al. Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer. 126(6):2334-40. PMID: 27159395
44. Bouffet et al. Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency. *J. Clin. Oncol.* 2016 Jul 1;34(19):2206-11. PMID: 27001570
45. Humphris et al. Hypermutation In Pancreatic Cancer. *Gastroenterology.* 2017 Jan;152(1):68-74.e2. PMID: 27856273
46. Bonneville et al. Landscape of Microsatellite Instability Across 39 Cancer Types. *JCO Precis Oncol.* 2017;2017. PMID: 29850653
47. Snyder et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. *N. Engl. J. Med.* 2014 Dec 4;371(23):2189-2199. PMID: 25409260
48. Alexandrov et al. Signatures of mutational processes in human cancer. *Nature.* 2013 Aug 22;500(7463):415-21. PMID: 23945592
49. Rizvi et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. *Science.* 2015 Apr 3;348(6230):124-8. PMID: 25765070
50. Van et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. *Science.* 2015 Oct 9;350(6257):207-211. PMID: 26359337
51. Chalmers et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. 9:34. PMID: 28420421
52. Govindan et al. Genomic landscape of non-small cell lung cancer in smokers and never-smokers. *Cell.* 2012 Sep 14;150(6):1121-34. PMID: 22980976
53. Endris et al. Measurement of tumor mutational burden (TMB) in routine molecular diagnostics: in silico and real-life analysis of three larger gene panels. *Int. J. Cancer.* 2019 May 1;144(9):2303-2312. PMID: 30446996
54. Meléndez et al. Methods of measurement for tumor mutational burden in tumor tissue. *Transl Lung Cancer Res.* 2018 Dec;7(6):661-667. PMID: 30505710
55. Hellmann et al. Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden. *N. Engl. J. Med.* 2018 May 31;378(22):2093-2104. PMID: 29658845
56. Ready et al. First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers. *J. Clin. Oncol.* 2019 Apr 20;37(12):992-1000. PMID: 30785829

References (continued)

57. Alborelli et al. Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer. *J. Pathol.* 2020 Jan;250(1):19-29. PMID: 31471895
58. Heeke et al. In-house Implementation of Tumor Mutational Burden Testing to Predict Durable Clinical Benefit in Non-small Cell Lung Cancer and Melanoma Patients. *Cancers (Basel)*. 2019 Aug 29;11(9). PMID: 31470674
59. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125514s123lbl.pdf
60. F. et al. CheckMate 817: First-Line Nivolumab + Ipilimumab in Patients with ECOG PS 2 and Other Special Populations with Advanced NSCLC. Volume 14, Issue 10, Supplement, Pages S214–S215. Abstract OA04.02
61. Zhu et al. Association Between Tumor Mutation Burden (TMB) and Outcomes of Cancer Patients Treated With PD-1/PD-L1 Inhibitions: A Meta-Analysis. *Front Oncol*, 9:1161, 04 Nov 2019. PMID: 31258479
62. Castellanos et al. Tumor mutational burden (TMB) and PD-L1 expression as predictors of response to immunotherapy (IO) in NSCLC. *Journal of Clinical Oncology* 37, no. 15_suppl (May 20, 2019) 2630-2630. Abstract 2630
63. NCCN Guidelines® - NCCN-Non-Small Cell Lung Cancer [Version 3.2022]
64. NCCN Guidelines® - NCCN-Bone Cancer [Version 2.2022]
65. NCCN Guidelines® - NCCN-Head and Neck Cancers [Version 2.2022]
66. NCCN Guidelines® - NCCN-Testicular Cancer [Version 2.2022]
67. NCCN Guidelines® - NCCN-Cervical Cancer [Version 1.2022]
68. NCCN Guidelines® - NCCN-Uterine Neoplasms [Version 1.2022]
69. NCCN Guidelines® - NCCN-Thyroid Carcinoma [Version 2.2022]
70. NCCN Guidelines® - NCCN-Esophageal and Esophagogastric Junction Cancers [Version 2.2022]
71. NCCN Guidelines® - NCCN-Ovarian Cancer [Version 1.2022]
72. NCCN Guidelines® - NCCN-Breast Cancer [Version 3.2022]
73. <https://www.focr.org/tmb>
74. <http://www.iqnpath.org/category/tmb>
75. Stenzinger et al. Tumor mutational burden standardization initiatives: Recommendations for consistent tumor mutational burden assessment in clinical samples to guide immunotherapy treatment decisions. *Genes Chromosomes Cancer*. 2019 Aug;58(8):578-588. PMID: 30664300
76. Merino et al. Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project. *J Immunother Cancer*. 2020 Mar;8(1). PMID: 32217756